Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1

BACKGROUND: Immune checkpoint inhibitors (ICIs) treatment is a breakthrough in managing metastatic solid tumours, but its use is associated with a high financial burden for public health care systems. Validated tools such as the European Society for Medical Oncology-Magnitude of Clinical Benefit Sca...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:ESMO Open
Autores principales: Pichler, M., Steyrer, J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8253953/
https://ncbi.nlm.nih.gov/pubmed/34175674
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100198
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares